A new benzophenone with biological activities purified from SWZ01.

Strain SZW01 was isolated from sea sediment collected from Shenzhen in Guangdong province, China, and was later identified as by16S rDNA sequence analysis. Various chromatographic processes led to the isolation and purification of three compounds from the fermentation culture of SZW01, including a new compound, 2,6'-dihydroxy-2,4'dimethoxy-8'-methyl-6-methoxy-acyl-ethyl-diphenylmethanone (), and two known compounds: fumigaclavine C () and alternarosin A (), as characterised by UV, IR, 1 D, 2 D-NMR and MS data. The antioxidant and α-glucosidase inhibitory activities of these compounds were evaluated.

The cost-effectiveness of a NSCLC patient assistance program for pemetrexed maintenance therapy in People's Republic of China.

Background: Eli Lilly and the China Primary Health Care Foundation are currently implementing a patient assistance program (PAP) in China, which allows first-line nonsquamous non-small-cell lung cancer (NSCLC) patients who complete four cycles of pemetrexed induction therapy to receive free, continuous pemetrexed maintenance therapy.

Objective: To estimate the cost-effectiveness of pemetrexed maintenance therapy vs basic standard care (BSC) and the economic impacts of providing a PAP for pemetrexed maintenance therapy to NSCLC patients who have completed pemetrexed induction therapy in a Chinese health care setting.

Methods: We developed a novel decision-analytic model to evaluate the long-term costs and clinical efficacy of pemetrexed plus BSC vs BSC alone.